Genscript Biotech Corporation Tangible Net Worth Ratio
Genscript Biotech Corporation tangible net worth ratio. Genscript Biotech Corporation (G51) has a Tangible Net Worth Ratio of 99.7% as of December 2025. This metric is calculated by deducting intangible assets (€13.25 Million) from net assets (€3.96 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore net asset momentum of Genscript Biotech Corporation to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Tangible Net Worth Ratio of Genscript Biotech Corporation (2016–2025)
Tangible net worth ratio of Genscript Biotech Corporation from 2016 to 2025. This chart shows how Genscript Biotech Corporation's Tangible Net Worth Ratio has changed across 10 annual periods from 2016 to 2025. As of December 2025, the ratio stands at 99.7%, reflecting net assets of €3.96 Billion with intangible assets of €13.25 Million EUR. Check how strategically is Genscript Biotech Corporation's equity deployed to assess the company's strategic physical and investment asset allocation.
Genscript Biotech Corporation Tangible Net Worth Ratio by Year (2016–2025)
Genscript Biotech Corporation tangible net worth ratio by year from 2016 to 2025. The table below presents the year-by-year Tangible Net Worth Ratio for Genscript Biotech Corporation from 2016 to 2025, covering 10 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see Genscript Biotech Corporation (G51) market capitalisation.
| Year | Tangible NW Ratio | Net Assets (EUR) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 99.7% | €3.96 Billion | €13.25 Million | €4.85 Billion | ▼ 0.0 pp |
| 2024 | 99.7% | €4.32 Billion | €13.04 Million | €5.28 Billion | ▲ +0.6 pp |
| 2023 | 99.1% | €2.04 Billion | €18.65 Million | €3.39 Billion | ▲ +0.8 pp |
| 2022 | 98.3% | €1.36 Billion | €23.81 Million | €2.55 Billion | ▲ +0.7 pp |
| 2021 | 97.6% | €1.09 Billion | €26.42 Million | €2.23 Billion | ▲ +3.8 pp |
| 2020 | 93.8% | €815.59 Million | €50.62 Million | €1.45 Billion | ▲ +0.6 pp |
| 2019 | 93.2% | €372.30 Million | €25.48 Million | €889.41 Million | ▼ -2.9 pp |
| 2018 | 96.0% | €493.30 Million | €19.64 Million | €916.98 Million | ▼ -2.9 pp |
| 2017 | 98.9% | €228.32 Million | €2.47 Million | €504.26 Million | ▲ +0.1 pp |
| 2016 | 98.8% | €184.02 Million | €2.13 Million | €226.03 Million | — |